Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2640-2645

  He, X X ^a   Tu, S M ^a   Lee, M H ^a   Yeung, S C J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Metformin; Overall survival; Prostate cancer; Thiazolidinediones

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN; INSULIN RECEPTOR; METFORMIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES;

EID: 80053504259     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr020     Document Type: Article

References (53)

1. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001; 84: 417-422.
2. Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 2003; 26: 1047-1051.
3. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2: 48-53.
4. Coughlin SS, Calle EE, Teras LR et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-1167.
5. Giovannucci E, Rimm EB, Stampfer MJ et al. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998; 9: 3-9.
6. Rosenberg DJ, Neugut AI, Ahsan H, Shea S. Diabetes mellitus and the risk of prostate cancer. Cancer Invest 2002; 20: 157-165.
7. Zhu K, Lee IM, Sesso HD et al. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004; 159: 978-982.
8. Coker AL, Sanderson M, Zheng W, Fadden MK. Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer 2004; 90: 2171-2175.
9. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071-1078.
10. Rodriguez C, Patel AV, Mondul AM et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-152.
11. Gonzalez-Perez A, Garcia Rodriguez LA. Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005; 16: 1055-1058.
12. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-2062.
13. Waters KM, Henderson BE, Stram DO et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009; 169: 937-945.
14. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009; 124: 1398-1403.
15. Gudmundsson J, Sulem P, Steinthorsdottir V et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-983.
16. Meyer TE, Boerwinkle E, Morrison AC et al. Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev 2010; 19: 558-565.
17. Pierce BL, Ahsan H. Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered 2010; 69: 193-201.
18. Stevens VL, Ahn J, Sun J et al. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 2010; 70: 601-607.
19. Gapstur SM, Gann PH, Colangelo LA et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 2001; 12: 763-772.
20. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-2895.
21. D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1329-1337.
22. Snyder CF, Stein KB, Barone BB et al. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 2010; 13: 58-64.
23. Ribeiro DL, Taboga SR, Goes RM. Diabetes induces stromal remodelling and increase in chondroitin sulphate proteoglycans of the rat ventral prostate. Int J Exp Pathol 2009; 90: 400-411.
24. Li D, Yeung SC, Hassan MM et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-488.
25. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
26. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009; 20: 1617-1622.
27. Govindarajan R, Ratnasinghe L, Simmons DL et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476-1481.
28. Galli A, Mello T, Ceni E et al. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs 2006; 15: 1039-1049.
29. Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents. Cancer Ther 2008; 6: 25-34.
30. Wei S, Yang J, Lee SL et al. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett 2009; 276: 119-124.
31. Efferth T, Sauerbrey A, Steinbach D et al. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol 2003; 23: 509-517.
32. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 2008; 67: 1-7.
33. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507-7511.
34. Zakikhani M, Dowling R, Fantus IG et al. Metformin is an AMP kinasedependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273.
35. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
36. Ben Sahra I, Laurent K, Loubat A et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586.
37. Xiang X, Saha AK, Wen R et al. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004; 321: 161-167.
38. Mueller E, Smith M, Sarraf P et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 2000; 97: 10990-10995.
39. Smith MR, Manola J, Kaufman DS et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004; 101: 1569-1574.
40. Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996; 155: 1667-1673.
41. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 485-492.
42. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 2008; 168: 925-931.
43. Velicer CM, Dublin S, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2007; 10: 46-51.
44. Shiau CW, Yang CC, Kulp SK et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005; 65: 1561-1569.
45. Feng YH, Velazquez-Torres G, Gully C et al. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 2010 May 3. [Epub ahead of print].
46. Zhao H, Dupont J, Yakar S et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004; 23: 786-794.
47. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010; 363: 1489-1491.
48. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310: 71-81.
49. Takada I, Kouzmenko AP, Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 2009; 5: 442-447.
50. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-1308.
51. Basaria S, Muller DC, Carducci MA et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-588.
52. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46.
53. Inaba M, Otani Y, Nishimura K et al. Marked hyperglycemia after androgendeprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 2005; 54: 55-59.